Skip to content

Application of indocyanine green fluorescence angiography in preventing anastomotic recurrence after Crohn’s disease intestinal resection and anastomosis: a single-center, prospective, randomized controlled trial

Application of indocyanine green fluorescence angiography in preventing anastomotic recurrence after Crohn’s disease intestinal resection and anastomosis: a single-center, prospective, randomized controlled trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000035737
Enrollment
Unknown
Registered
2020-08-16
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's disease

Interventions

Experimental group:The scope of surgical resection was determined by indocyanine green fluorescence angiography
Control group:The scope of surgical resection (2cm away from the lesion site) determined by the physician based on experience

Sponsors

Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) A patient diagnosed with Crohn's disease meets the diagnostic criteria established by the "Consensus Opinions on the Diagnosis and Treatment of Inflammatory Bowel Disease (2018, Beijing)" by the Inflammatory Bowel Disease Group of the Chinese Medical Association Gastroenterology Branch; 2) Voluntary acceptance and signed informed consent; 3) Aged 18-70 years old; 4) Those who can communicate well with researchers and complete the experiment process; 5) For patients who have been clinically diagnosed as CD and have indications for surgery, the indications for surgery are based on the standards established by the "Consensus on the Diagnosis and Treatment of Inflammatory Bowel Disease (2018, Beijing)".

Exclusion criteria

Exclusion criteria: 1) People who are allergic to iodine, or are allergic to multiple drugs; 2) Patients with severe cardiopulmonary dysfunction, renal failure, and acute cardio-cerebrovascular accident; 3) The patient has signs of malignant tumor recurrence or metastasis; 4) Patients with clear diagnosis of CD but no indication of surgical treatment.

Design outcomes

Primary

MeasureTime frame
Endoscopic recurrence of Crohn's disease;

Countries

China

Contacts

Public ContactYantao Duan

Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine

sdfcdythewa@163.com+86 18317032326

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026